Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy

Stambas, J., Brown, S.A., Gutierrez, A., Sealy, R., Yue, W., Jones, B., Lockey, T.D., Zirkel, A., Freiden, P., Brown, B., Surman, S., Coleclough, C., Slobod, K.S., Doherty, P.C. and Hurwitz, J.L. 2005, Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy, Vaccine, vol. 23, no. 19, pp. 2454-2464.

Attached Files
Name Description MIMEType Size Downloads

Title Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy
Author(s) Stambas, J.
Brown, S.A.
Gutierrez, A.
Sealy, R.
Yue, W.
Jones, B.
Lockey, T.D.
Zirkel, A.
Freiden, P.
Brown, B.
Surman, S.
Coleclough, C.
Slobod, K.S.
Doherty, P.C.
Hurwitz, J.L.
Journal name Vaccine
Volume number 23
Issue number 19
Start page 2454
End page 2464
Publisher Elsevier Ltd.
Place of publication Guildford, England
Publication date 2005-03-31
ISSN 0264-410X
1873-2518
Keyword(s) prime-boost regimen
durable
serum/mucosal
Summary Despite decades of work, an effective HIV vaccine remains elusive. In an effort to elicit protective immunity, investigators have sought to define vaccines able to elicit durable HIV-specific B-cell and T-cell activities. Additionally, vaccines are sought which can induce antibodies of a variety of isotypes, as each isotype possesses unique attributes in terms of opsonization, Fc receptor binding capacity, complement fixation and location. One prominent new vaccine strategy, applied to numerous distinct antigenic systems is the prime boost-regimen, with DNA, vaccinia virus (VV), and/or purified recombinant protein. To examine the durability, location and isotype distribution of responses induced by prime-boost regimens, we tested successive immunizations with DNA, VV and protein (D-V-P), comparing three forms of protein inoculations: (i) purified protein administered intramuscularly with complete Freunds adjuvant, (ii) purified protein administered intranasally, and (iii) purified protein conjugated to oxidized mannan, administered intranasally. We found that all three protocols elicited serum antibodies of multiple isotypes, with serum IgA being most prominent among mice immunized with mannan-conjugated protein. All D-V-P protocols, regardless of protein form or route, also elicited antibody responses at mucosal surfaces. In bronchoalveolar lavage, a tendency toward IgA production was again most prominent in mice boosted with the protein–mannan conjugate. Both B-cell and T-cell responses were sustained for more than 1 year post-immunization following each form of vaccination. Contemporaneous with long-lasting serum and mucosal antibodies were antibody forming cells in the bone marrow of primed animals. Results highlight the D-V-P vaccination strategy as a promising approach for attaining durable, multi-isotype B-cell and T-cell activities toward HIV.
Language eng
Field of Research 110804 Medical Virology
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ┬ęCopyright 2004 Elsevier Ltd All rights reserved.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30028909

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 25 times in TR Web of Science
Scopus Citation Count Cited 10 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 290 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 26 May 2010, 16:07:17 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.